Abbott Laboratories (ABT) Osake Kurssi
Abbott Laboratories Kurssi
Viimeisten 19 vuoden aikana Abbott Laboratoriesn liikevaihto kasvoi 3,6 % vuodessa ja ylsi 44,33 Mrd. USD:een. Osakekohtainen tulos on kasvanut 6,6 % vuodessa viimeisten 19 vuoden aikana. Abbott Laboratoriesn nettomarginaali 14,7 % on laskenut verrattuna 16,4 %:iin muutama vuosi sitten. Nykyhinnalla osinkotuotto on noin 2,37 %. Jakosuhde on noin 63 % tuloksesta. Osinko on kasvanut 3,8 % vuodessa viimeisten 19 vuoden aikana. Abbott Laboratoriesn 12 kuukauden konsensustavoitehinta on 121,00 USD, noin yli kurssia 21,7 %. 33 analyytikosta 25 suosittaa ostoa — kokonaiskonsensus on Osta.
Abbott Laboratories osakekurssi
Abbott Laboratories liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Abbott Laboratories -osakkeesta
Abbott Laboratories is a renowned healthcare company with a strong business model focused on providing a diverse range of medical products, diagnostics, nutritional supplements, and pharmaceuticals. By combining technological advancements with innovative research, Abbott aims to enhance the quality of life for individuals worldwide. With a comprehensive portfolio spanning diverse healthcare sectors, including diagnostics, nutrition, diabetes care, medical devices, and branded generic pharmaceuticals, Abbott Laboratories strives to improve patient outcomes and deliver sustainable growth. Through its commitment to scientific excellence and dedication to meeting evolving healthcare needs, Abbott Laboratories has established itself as a trusted leader in the global healthcare industry.
Abbott Laboratories is primarily active in the healthcare industry.
The main competitors of Abbott Laboratories in the market are Johnson & Johnson, Pfizer, and Roche Holding AG.
Abbott Laboratories is a renowned American healthcare company, known for providing a diverse range of medical, pharmaceutical, and nutritional products. Founded in 1888 by Dr. Wallace C. Abbott, the company initially focused on producing pharmaceuticals, including the widely successful alkaloid-based pain reliever, Abbott's ABC Liniment. Over the years, Abbott Laboratories has expanded its portfolio, venturing into areas such as diagnostics, medical devices, and nutrition. The company's commitment to innovation is evident through breakthroughs like the development of the first HIV blood-screening test. Today, Abbott Laboratories continues to play a crucial role in improving health outcomes worldwide, with its cutting-edge technology and a focus on delivering quality healthcare solutions.
Abbott Laboratories has achieved several significant milestones throughout its history. One major milestone was the development and commercialization of the first-ever HIV blood screening test, which greatly contributed to safer transfusions and the prevention of the spread of HIV. Additionally, Abbott Laboratories introduced breakthrough medical devices, such as the FreeStyle® Libre system, a continuous glucose monitoring system for diabetes management. The company also played a crucial role in the fight against COVID-19 by developing rapid diagnostic tests for the virus. Furthermore, Abbott Laboratories has consistently been recognized for its commitment to innovation and sustainability, making it a leading healthcare company globally.
Abbott Laboratories is primarily present in multiple countries and regions worldwide. The company operates in more than 160 countries, including the United States, Canada, Europe, Asia-Pacific, Latin America, and the Middle East. With a strong global footprint, Abbott Laboratories has established itself as a leading healthcare company in various markets, delivering innovative medical products, diagnostics, nutritionals, and pharmaceuticals to improve people's health and well-being.
Abbott Laboratories is committed to its core values of putting patients first, serving customers with innovative solutions, and operating with integrity in all aspects of its business. The company's corporate philosophy centers around improving life through the development of groundbreaking technologies and products. Abbott Laboratories prides itself on its dedication to delivering reliable healthcare solutions, fostering collaboration with healthcare professionals, and investing in research and development to address unmet medical needs. With a focus on providing high-quality and accessible healthcare options, Abbott Laboratories strives to create positive impacts in communities worldwide through its diverse portfolio of medical devices, diagnostics, nutrition, and pharmaceutical products.
Analyytikot asettavat tällä hetkellä Abbott Laboratories-osakkeelle keskimääräisen tavoitehinnan 123,64 USD (mediaani: 121,00 USD), mikä merkitsee +24,4 % viimeisimpään hintaan verrattuna. Konsensus perustuu 33 analyytikkoarvioon.
33 analyytikkoa arvioi tällä hetkellä Abbott Laboratories-osaketta: 25 suosittaa ostoa, 8 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Abbott Laboratories-yhtiöltä 50,31 Mrd. USD liikevaihtoa ja 5,52 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Abbott Laboratories-osake noteerataan hintaan 88,70 EUR (99,40 USD).
Abbott Laboratories-osake (ABT) on listattuna 9 pörssissä, muun muassa: NYSE (ABT), London (0Q15.L), SIX (Zürich) (ABT.SW), XETRA (ABL.DE), Frankfurt (ABL.F), München (ABL.MU), Düsseldorf (ABL.DU), Hamburg (ABL.HM).
Abbott Laboratories is a global company specializing in the development, manufacturing, and marketing of health products and services. Its business model is divided into different divisions that focus on the needs of patients, doctors, and healthcare systems. The divisions of Abbott Laboratories include Diagnostics, Medical Devices, Nutrition, and Pharmaceutical. The company aims to continuously develop innovative technologies and products to improve healthcare, and it offers a wide range of services and support programs for patients. Abbott Laboratories has established a strong market position and global presence in over 160 countries since its establishment in 1888. It also pursues a successful acquisition strategy to expand its product portfolio, such as the acquisition of St. Jude Medical in 2017 to enhance its cardiovascular products and services. Overall, Abbott Laboratories aims to improve healthcare and meet the needs of patients, doctors, and healthcare systems through its comprehensive strategy focused on developing innovative products, expanding into new markets, and increasing efficiency.
odotettu liikevaihto Abbott Laboratories on 50,31 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Abbott Laboratories on 9,64 Mrd. USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Abbott Laboratories:n hinta-voitto-suhde (P/E) on tällä hetkellä 18,01. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Abbott Laboratories-osakkeen arvostusta.
Abbott Laboratories:n hinta-myynti-suhde (P/S) on tällä hetkellä 3,45. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Abbott Laboratories-osakkeen arvostuskennuslukuna.
Abbott Laboratories:n Eulpool-laatuscore on 6/10.
Abbott Laboratories:n ISIN on US0028241000. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Abbott Laboratories:n WKN on 850103. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Abbott Laboratories:n ticker on ABT. Tämä pörssinoteeraus käytetään Abbott Laboratories-osakkeiden kauppaan pörssissä.
Abbott Laboratories osake
Abbott Laboratories vertaisryhmä
Abbott Laboratories Ticker
Abbott Laboratories FIGI
Kaikki tunnusluvut ja syvällinen analyysi Abbott Laboratories:sta
Meidän osakeanalyysimme Abbott Laboratories-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Abbott Laboratories:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: